{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:58:48Z","timestamp":1790459928449,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21EB021103"],"award-info":[{"award-number":["R21EB021103"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB009041"],"award-info":[{"award-number":["R01EB009041"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21EB021103"],"award-info":[{"award-number":["R21EB021103"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB009041"],"award-info":[{"award-number":["R01EB009041"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21EB021103"],"award-info":[{"award-number":["R21EB021103"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB009041"],"award-info":[{"award-number":["R01EB009041"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21EB021103"],"award-info":[{"award-number":["R21EB021103"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB009041"],"award-info":[{"award-number":["R01EB009041"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21EB021103"],"award-info":[{"award-number":["R21EB021103"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB009041"],"award-info":[{"award-number":["R01EB009041"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21EB021103"],"award-info":[{"award-number":["R21EB021103"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB009041"],"award-info":[{"award-number":["R01EB009041"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Focused ultrasound-enhanced intranasal (IN\u2009+\u2009FUS) delivery is a noninvasive approach that utilizes the olfactory pathway to administer pharmacological agents directly to the brain, allowing for a more homogenous distribution in targeted locations compared to IN delivery alone. However, whether such a strategy has therapeutic values, especially in neurodegenerative disorders such as Parkinson\u2019s disease (PD), remains to be established. Herein, we evaluated whether the expression of tyrosine hydroxylase (TH), the rate limiting enzyme in dopamine catalysis, could be enhanced by IN\u2009+\u2009FUS delivery of brain-derived neurotrophic factor (BDNF) in a toxin-based PD mouse model. Mice were put on the subacute dosing regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), producing bilateral degeneration of the nigrostriatal pathway consistent with early-stage PD. MPTP mice then received BDNF intranasally followed by multiple unilateral FUS-induced blood-brain barrier (BBB) openings in the left basal ganglia for three consecutive weeks. Subsequently, mice were survived for two months and were evaluated morphologically and behaviorally to determine the integrity of their nigrostriatal dopaminergic pathways. Mice receiving IN\u2009+\u2009FUS had significantly increased TH immunoreactivity in the treated hemisphere compared to the untreated hemisphere while mice receiving only FUS-induced BBB opening or no treatment at all did not show any differences. Additionally, behavioral changes were only observed in the IN\u2009+\u2009FUS treated mice, indicating improved motor control function in the treated hemisphere. These findings demonstrate the robustness of the method and potential of IN\u2009+\u2009FUS for the delivery of bioactive factors for treatment of neurodegenerative disorder.<\/jats:p>","DOI":"10.1038\/s41598-019-55294-5","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T06:02:55Z","timestamp":1576648975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson\u2019s disease mouse model"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1361-141X","authenticated-orcid":false,"given":"Robin","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8368-1360","authenticated-orcid":false,"given":"Maria E.","family":"Karakatsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernice","family":"Jackson-Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Przedborski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa E.","family":"Konofagou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"key":"55294_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"NJ Abbott","year":"2013","unstructured":"Abbott, N. J. Blood\u2013brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis. 36, 437\u2013449 (2013).","journal-title":"J. Inherit. Metab. Dis."},{"key":"55294_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/cbdd.12268","volume":"83","author":"J Stockwell","year":"2014","unstructured":"Stockwell, J., Abdi, N., Lu, X., Maheshwari, O. & Taghibiglou, C. Novel Central Nervous System Drug Delivery Systems. Chem. Biol. Drug Des. 83, 507\u2013520 (2014).","journal-title":"Chem. Biol. Drug Des."},{"key":"55294_CR3","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge, W. M. Drug Transport across the Blood\u2013Brain Barrier. J. Cereb. Blood Flow Metab. 32, 1959\u20131972 (2012).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"55294_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva, C. et al. Nanoparticle-mediated brain drug delivery: Overcoming blood\u2013brain barrier to treat neurodegenerative diseases. J. Control. Release 235, 34\u201347 (2016).","journal-title":"J. Control. Release"},{"key":"55294_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","volume":"87","author":"L Illum","year":"2003","unstructured":"Illum, L. Nasal drug delivery\u2014possibilities, problems and solutions. J. Control. Release 87, 187\u2013198 (2003).","journal-title":"J. Control. Release"},{"key":"55294_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0169-409X(01)00174-0","volume":"51","author":"R Glueck","year":"2001","unstructured":"Glueck, R. Review of intranasal influenza vaccine. Adv. Drug Deliv. Rev. 51, 203\u201311 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"55294_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2165\/00003088-200140120-00003","volume":"40","author":"RG Thorne","year":"2001","unstructured":"Thorne, R. G. & Frey, W. H. Delivery of Neurotrophic Factors to the Central Nervous System. Clin. Pharmacokinet. 40, 907\u2013946 (2001).","journal-title":"Clin. Pharmacokinet."},{"key":"55294_CR8","doi-asserted-by":"crossref","unstructured":"Hammarlund-udenaes, M. & Lange, E. C. M. De & Editors, R. G. T. Drug Delivery to the Brain. 10, (Springer New York, 2014).","DOI":"10.1007\/978-1-4614-9105-7"},{"key":"55294_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymthe.2006.02.018","volume":"14","author":"P Hadaczek","year":"2006","unstructured":"Hadaczek, P. et al. The \u201cPerivascular Pump\u201d Driven by Arterial Pulsation Is a Powerful Mechanism for the Distribution of Therapeutic Molecules within the Brain. Mol. Ther. 14, 69\u201378 (2006).","journal-title":"Mol. Ther."},{"key":"55294_CR10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead, J. J. & Thorne, R. G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 64, 614\u2013628 (2012).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"55294_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep31732","volume":"6","author":"NN Kumar","year":"2016","unstructured":"Kumar, N. N. et al. Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery. Sci. Rep. 6, 31732 (2016).","journal-title":"Sci. Rep."},{"key":"55294_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.nano.2018.11.006","volume":"16","author":"AEE Aly","year":"2019","unstructured":"Aly, A. E. E. et al. Intranasal delivery of hGDNF plasmid DNA nanoparticles results in long-term and widespread transfection of perivascular cells in rat brain. Nanomedicine. Nanotechnology, Biol. Med. 16, 20\u201333 (2019).","journal-title":"Nanotechnology, Biol. Med."},{"key":"55294_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/gt.2014.28","volume":"21","author":"BT Harmon","year":"2014","unstructured":"Harmon, B. T. et al. Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. Gene Ther. 21, 514\u201321 (2014).","journal-title":"Gene Ther."},{"key":"55294_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.apsb.2016.04.001","volume":"6","author":"T Lin","year":"2016","unstructured":"Lin, T. et al. Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharm. Sin. B 6, 352\u2013358 (2016).","journal-title":"Acta Pharm. Sin. B"},{"key":"55294_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3109\/10717544.2013.860501","volume":"22","author":"PR Ravi","year":"2015","unstructured":"Ravi, P. R., Aditya, N., Patil, S. & Cherian, L. Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv. 22, 903\u2013910 (2015).","journal-title":"Drug Deliv."},{"key":"55294_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/jcbfm.2014.215","volume":"35","author":"JJ Lochhead","year":"2015","unstructured":"Lochhead, J. J., Wolak, D. J., Pizzo, M. E. & Thorne, R. G. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J. Cereb. Blood Flow Metab. 35, 371\u2013381 (2015).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"55294_CR17","doi-asserted-by":"publisher","first-page":"e108880","DOI":"10.1371\/journal.pone.0108880","volume":"9","author":"H Chen","year":"2014","unstructured":"Chen, H. et al. A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery. PLoS One 9, e108880 (2014).","journal-title":"PLoS One"},{"key":"55294_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep28599","volume":"6","author":"H Chen","year":"2016","unstructured":"Chen, H. et al. Focused ultrasound-enhanced intranasal brain delivery of brain-derived neurotrophic factor. Sci. Rep. 6, 28599 (2016).","journal-title":"Sci. Rep."},{"key":"55294_CR19","doi-asserted-by":"publisher","first-page":"034301","DOI":"10.1103\/PhysRevLett.106.034301","volume":"106","author":"H Chen","year":"2011","unstructured":"Chen, H., Kreider, W., Brayman, A. A., Bailey, M. R. & Matula, T. J. Blood Vessel Deformations on Microsecond Time Scales by Ultrasonic Cavitation. Phys. Rev. Lett. 106, 034301 (2011).","journal-title":"Phys. Rev. Lett."},{"key":"55294_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0301-0082(00)00014-9","volume":"63","author":"M Murer","year":"2001","unstructured":"Murer, M., Yan, Q. & Raisman-Vozari, R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer\u2019s disease and Parkinson\u2019s disease. Prog. Neurobiol. 63, 71\u2013124 (2001).","journal-title":"Prog. Neurobiol."},{"key":"55294_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0304-3940(99)00463-2","volume":"270","author":"M Mogi","year":"1999","unstructured":"Mogi, M. et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson\u2019s disease. Neurosci. Lett. 270, 45\u201348 (1999).","journal-title":"Neurosci. Lett."},{"key":"55294_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/exnr.2000.7483","volume":"166","author":"DW Howells","year":"2000","unstructured":"Howells, D. W. et al. Reduced BDNF mRNA Expression in the Parkinson\u2019s Disease Substantia Nigra. Exp. Neurol. 166, 127\u2013135 (2000).","journal-title":"Exp. Neurol."},{"key":"55294_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","volume":"5","author":"C Zuccato","year":"2009","unstructured":"Zuccato, C. & Cattaneo, E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5, 311\u2013322 (2009).","journal-title":"Nat. Rev. Neurol."},{"key":"55294_CR24","doi-asserted-by":"crossref","unstructured":"Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O. & Hashimoto, N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 37, 733\u20139; discussion 739-41 (1995).","DOI":"10.1097\/00006123-199510000-00018"},{"key":"55294_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet (London, England) 386, 896\u2013912 (2015).","journal-title":"Lancet (London, England)"},{"key":"55294_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2010.12.017","volume":"508","author":"SC Daubner","year":"2011","unstructured":"Daubner, S. C., Le, T. & Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys. 508, 1\u201312 (2011).","journal-title":"Arch. Biochem. Biophys."},{"key":"55294_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jconrel.2019.03.030","volume":"303","author":"ME Karakatsani","year":"2019","unstructured":"Karakatsani, M. E. et al. Amelioration of the nigrostriatal pathway facilitated by ultrasound-mediated neurotrophic delivery in early Parkinson\u2019s disease. J. Control. Release 303, 289\u2013301 (2019).","journal-title":"J. Control. Release"},{"key":"55294_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979\u201380 (1983).","journal-title":"Science"},{"key":"55294_CR29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1126\/science.1068613","volume":"296","author":"MC Raff","year":"2002","unstructured":"Raff, M. C., Whitmore, A. V. & Finn, J. T. Neuroscience: Axonal self-destruction and neurodegeneration. Science 296, 868\u2013871 (2002).","journal-title":"Science"},{"key":"55294_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tins.2007.02.004","volume":"30","author":"L Conforti","year":"2007","unstructured":"Conforti, L., Adalbert, R. & Coleman, M. P. Neuronal death: where does the end begin? Trends Neurosci. 30, 159\u2013166 (2007).","journal-title":"Trends Neurosci."},{"key":"55294_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0022-510X(97)00100-7","volume":"151","author":"SY Ma","year":"1997","unstructured":"Ma, S. Y., R\u00f6ytt\u00e4, M., Rinne, J. O., Collan, Y. & Rinne, U. K. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson\u2019s disease using disector counts. J. Neurol. Sci. 151, 83\u201387 (1997).","journal-title":"J. Neurol. Sci."},{"key":"55294_CR32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/archneur.63.4.584","volume":"63","author":"S Greffard","year":"2006","unstructured":"Greffard, S. et al. Motor score of the unified Parkinson disease rating scale as a good predictor of lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 63, 584\u2013588 (2006).","journal-title":"Arch. Neurol."},{"key":"55294_CR33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","volume":"67","author":"H-C Cheng","year":"2010","unstructured":"Cheng, H.-C., Ulane, C. M. & Burke, R. E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715\u2013725 (2010).","journal-title":"Ann. Neurol."},{"key":"55294_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis, V. & Przedborski, S. Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat. Protoc. 2, 141\u2013151 (2007).","journal-title":"Nat. Protoc."},{"key":"55294_CR35","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0306-4522(96)00545-3","volume":"77","author":"NA Tatton","year":"1997","unstructured":"Tatton, N. A. & Kish, S. J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77, 1037\u201348 (1997).","journal-title":"Neuroscience"},{"key":"55294_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jconrel.2018.08.006","volume":"286","author":"NN Kumar","year":"2018","unstructured":"Kumar, N. N. et al. Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery. J. Control. Release 286, 467\u2013484 (2018).","journal-title":"J. Control. Release"},{"key":"55294_CR37","unstructured":"Lindgren, Hanna S. & Lane, E. L. Animal Models of Movement Disorders. Animal Models of Movement Disorders. 61 (Humana Press, 2012)."},{"key":"55294_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/exnr.1998.6848","volume":"152","author":"D Kirik","year":"1998","unstructured":"Kirik, D., Rosenblad, C. & Bj\u00f6rklund, A. Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat. Exp. Neurol. 152, 259\u2013277 (1998).","journal-title":"Exp. Neurol."},{"key":"55294_CR39","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/00001756-199601310-00060","volume":"7","author":"CW Shults","year":"1996","unstructured":"Shults, C. W., Kimber, T. & Martin, D. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. Neuroreport 7, 627\u2013631 (1996).","journal-title":"Neuroreport"},{"key":"55294_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.gt.3301682","volume":"9","author":"L Wang","year":"2002","unstructured":"Wang, L. et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson\u2019s disease. Gene Ther. 9, 381\u2013389 (2002).","journal-title":"Gene Ther."},{"key":"55294_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2017.00607","volume":"11","author":"ME Downs","year":"2017","unstructured":"Downs, M. E. et al. Toward a Cognitive Neural Prosthesis Using Focused Ultrasound. Front. Neurosci. 11, 1\u201316 (2017).","journal-title":"Front. Neurosci."},{"key":"55294_CR42","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","volume":"127","author":"RG Thorne","year":"2004","unstructured":"Thorne, R. G., Pronk, G. J., Padmanabhan, V. & Frey, W. H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481\u2013496 (2004).","journal-title":"Neuroscience"},{"key":"55294_CR43","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","volume":"152","author":"RG Thorne","year":"2008","unstructured":"Thorne, R. G., Hanson, L. R., Ross, T. M., Tung, D. & Frey, W. H. Delivery of interferon-\u03b2 to the monkey nervous system following intranasal administration. Neuroscience 152, 785\u2013797 (2008).","journal-title":"Neuroscience"},{"key":"55294_CR44","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jconrel.2018.07.020","volume":"286","author":"D Ye","year":"2018","unstructured":"Ye, D. et al. Focused ultrasound combined with microbubble-mediated intranasal delivery of gold nanoclusters to the brain. J. Control. Release 286, 145\u2013153 (2018).","journal-title":"J. Control. Release"},{"key":"55294_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0169-409X(97)00064-1","volume":"29","author":"C Behl","year":"1998","unstructured":"Behl, C. et al. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv. Drug Deliv. Rev. 29, 117\u2013133 (1998).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"55294_CR46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0169-328X(95)00250-V","volume":"36","author":"JF Poduslo","year":"1996","unstructured":"Poduslo, J. F. & Curran, G. L. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Mol. Brain Res. 36, 280\u2013286 (1996).","journal-title":"Mol. Brain Res."},{"key":"55294_CR47","first-page":"738","volume":"11","author":"WM Pardridge","year":"1994","unstructured":"Pardridge, W. M., Kang, Y. S. & Buciak, J. L. Transport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat Blood\u2212Brain Barrier in Vivo Using Vector-Mediated Peptide. Drug Delivery. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 11, 738\u2013746 (1994).","journal-title":"Drug Delivery. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci."},{"key":"55294_CR48","doi-asserted-by":"publisher","first-page":"N65","DOI":"10.1088\/0031-9155\/57\/7\/N65","volume":"57","author":"B Baseri","year":"2012","unstructured":"Baseri, B. et al. Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood\u2013brain barrier using focused ultrasound and microbubbles. Phys. Med. Biol. 57, N65\u2013N81 (2012).","journal-title":"Phys. Med. Biol."},{"key":"55294_CR49","doi-asserted-by":"publisher","unstructured":"Jackson-Lewis, V., Lester, D., Kozina, E., Przedborski, S. & Smeyne, R. J. From Man to Mouse: The MPTP Model of Parkinson Disease. Mov. Disord. Genet. Model. Second Ed. 287\u2013306, https:\/\/doi.org\/10.1016\/B978-0-12-405195-9.00017-2 (2014).","DOI":"10.1016\/B978-0-12-405195-9.00017-2"},{"key":"55294_CR50","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/jcbfm.2014.236","volume":"35","author":"G Samiotaki","year":"2015","unstructured":"Samiotaki, G., Acosta, C., Wang, S. & Konofagou, E. E. Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood-brain barrier opening in vivo. J. Cereb. Blood Flow Metab. 35, 611\u201322 (2015).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"55294_CR51","doi-asserted-by":"publisher","first-page":"9079","DOI":"10.1088\/0031-9155\/60\/23\/9079","volume":"60","author":"T Sun","year":"2015","unstructured":"Sun, T. et al. Acoustic cavitation-based monitoring of the reversibility and permeability of ultrasound-induced blood-brain barrier opening. Phys. Med. Biol. 60, 9079\u20139094 (2015).","journal-title":"Phys. Med. Biol."},{"key":"55294_CR52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/jcbfm.2010.155","volume":"31","author":"JJ Choi","year":"2011","unstructured":"Choi, J. J. et al. Noninvasive and localized blood-brain barrier disruption using focused ultrasound can be achieved at short pulse lengths and low pulse repetition frequencies. J. Cereb. Blood Flow Metab. 31, 725\u2013737 (2011).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"55294_CR53","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jcis.2008.09.066","volume":"329","author":"JA Feshitan","year":"2009","unstructured":"Feshitan, J. A., Chen, C. C., Kwan, J. J. & Borden, M. A. Microbubble size isolation by differential centrifugation. J. Colloid Interface Sci. 329, 316\u2013324 (2009).","journal-title":"J. Colloid Interface Sci."},{"key":"55294_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1179\/175889709X446507","volume":"1","author":"SR Sirsi","year":"2009","unstructured":"Sirsi, S. R. & Borden, M. A. Microbubble compositions, properties and biomedical applications. Bubble Sci. Eng. Technol. 1, 3\u201317 (2009).","journal-title":"Bubble Sci. Eng. Technol."},{"key":"55294_CR55","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/0006-8993(85)90698-5","volume":"330","author":"RJ Mandel","year":"1985","unstructured":"Mandel, R. J. & Randall, P. K. Quantification of lesion-induced dopaminergic supersensitivity using the rotational model in the house. Brain Res. 330, 358\u2013363 (1985).","journal-title":"Brain Res."},{"key":"55294_CR56","unstructured":"Franklin, K. B. J. & Paxinos, G. The Mouse Brain in Stereotaxic Coordinates. (Elsevier\/Academic Press, 2008)."},{"key":"55294_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1017\/S1461145710000738","volume":"14","author":"AB Klein","year":"2011","unstructured":"Klein, A. B. et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int. J. Neuropsychopharmacol. 14, 347\u2013353 (2011).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"55294_CR58","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1007\/s12035-018-0890-6","volume":"55","author":"VS da Fons\u00eaca","year":"2018","unstructured":"da Fons\u00eaca, V. S. et al. Brain-Derived Neurotrophic Factor Prevents Depressive-Like Behaviors in Early-Symptomatic YAC128 Huntington\u2019s Disease Mice. Mol. Neurobiol. 55, 7201\u20137215 (2018).","journal-title":"Mol. Neurobiol."},{"key":"55294_CR59","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.neuroscience.2010.10.054","volume":"172","author":"Y Jiang","year":"2011","unstructured":"Jiang, Y. et al. Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 172, 398\u2013405 (2011).","journal-title":"Neuroscience"},{"key":"55294_CR60","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11095-011-0572-9","volume":"29","author":"SRK Vaka","year":"2012","unstructured":"Vaka, S. R. K., Murthy, S. N., Balaji, A. & Repka, M. A. Delivery of brain-derived neurotrophic factor via nose-to-brain pathway. Pharm. Res. 29, 441\u2013447 (2012).","journal-title":"Pharm. Res."},{"key":"55294_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/10611860903318134","volume":"18","author":"SR Alcal\u00e1-Barraza","year":"2010","unstructured":"Alcal\u00e1-Barraza, S. R. et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J. Drug Target. 18, 179\u2013190 (2010).","journal-title":"J. Drug Target."},{"key":"55294_CR62","doi-asserted-by":"publisher","first-page":"1703982","DOI":"10.1002\/adfm.201703982","volume":"28","author":"Y Jiang","year":"2018","unstructured":"Jiang, Y. et al. Nanoformulation of Brain-Derived Neurotrophic Factor with Target Receptor-Triggered-Release in the Central Nervous System. Adv. Funct. Mater. 28, 1703982 (2018).","journal-title":"Adv. Funct. Mater."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55294-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55294-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55294-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:41:33Z","timestamp":1671280893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55294-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["55294"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-55294-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,18]]},"assertion":[{"value":"21 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19402"}}